Myasthenia gravis and covid-19 in pregnancy: a review of the literature and case series report

Neykova, Konstantsa Krassimirova; Миланова, Милена; Ignatov, P

doi:10.1080/14767058.2021.1973418

Cited by 3 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, interrelations of symptoms, clinical outcomes, and treatment regimens in pregnant women, diagnosed with myasthenia gravis and superimposed COVID‐19 infection was also investigated. But, it yielded that the co‐occurrence of MG and COVID‐19 infection in pregnancy does not elicit exacerbation in either of those conditions (Neykova et al., 2021 ). However, since infections, in general, have been known to trigger and augment autoimmunity (Gilhus et al., 2018 ), this case can be taken as an initial step to establish the causal relationship between COVID‐19 and myasthenia crisis.…”

Section: Resultsmentioning

confidence: 99%

COVID‐19 and myasthenia gravis: A review of neurological implications of the SARS‐COV‐2

et al. 2022

View full text Add to dashboard Cite

Introduction:This review highlights the potential mechanisms of neuromuscular manifestation of COVID-19, especially myasthenia gravis (MG).Methods: An extensive literature search was conducted by two independent investigators using PubMed/MEDLINE and Google Scholar from its inception to December 2020. Results: Exacerbations of clinical symptoms in patients of MG who were treated with some commonly used COVID-19 drugs has been reported, with updated recommendations of management of symptoms of neuromuscular disorders. Severe acute respiratory syndrome coronavirus 2 can induce the immune response to trigger autoimmune neurological disorders. Conclusions: Further clinical studies are warranted to indicate and rather confirm if MG in the setting of COVID-19 can pre-existent subclinically or develop as a new-onset disease.

show abstract

Section: Resultsmentioning

confidence: 99%

COVID‐19 and myasthenia gravis: A review of neurological implications of the SARS‐COV‐2

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Recommendations for the treatment of MG in pregnancies complicated by COVID-19 have been summarized [ 8 ] and include acetylcholinesterase inhibitors, corticosteroids and low-dose aspirin. Care should be taken to try to find alternatives to magnesium sulfate, calcium-channel blockers, and β-adrenoceptor blockers, especially in light of the increased risk of preeclampsia in pregnancies associated with COVID-19 [ 9 , 10 ].…”

Section: Discussionmentioning

confidence: 99%

COVID-19 in a pregnant cystic fibrosis carrier with myasthenia gravis: A case report

Coté

Granger

Mishra

et al. 2022

Case Reports in Women's Health

View full text Add to dashboard Cite

Choices and Challenges With Treatment of Myasthenia Gravis in Pregnancy: A Systematic Review

Kumar,

Kachhadia,

Kaur

et al. 2023

Cureus

View full text Add to dashboard Cite

Myasthenia gravis (MG) is an autoimmune disease affecting young women in their second and third decades, coinciding with their reproductive years. We aim to explore the choices and challenges in the treatment of MG in pregnancy. Cochrane, PubMed, Google Scholar, and Embase were the four databases systematically searched for studies with patients reporting pregnancy outcomes for women with MG during pregnancy using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) technique. Quality assessment was done using the Joanna Briggs Institute critical tool (JBI, Adelaide, Australia) for methodological quality. From 2000 to 2023, 40 studies from database search results were considered. There is a substantial risk of complications with MG, especially if it appears during pregnancy. In particular, widespread weakness is a cause of severe, life-threatening disorders, but several treatment options are available.

show abstract

Myasthenia gravis and covid-19 in pregnancy: a review of the literature and case series report

Cited by 3 publications

References 41 publications

COVID‐19 and myasthenia gravis: A review of neurological implications of the SARS‐COV‐2

COVID‐19 and myasthenia gravis: A review of neurological implications of the SARS‐COV‐2

COVID-19 in a pregnant cystic fibrosis carrier with myasthenia gravis: A case report

Choices and Challenges With Treatment of Myasthenia Gravis in Pregnancy: A Systematic Review

Contact Info

Product

Resources

About